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5 studies were selected that reported appropriate data to assess test-retest reliability 
and 26 studies were selected which reported alpha coefﬁcient scores to determine the 
internal consistency of the HADS. Factor analysis studies revealed consistent bi-
dimensional or tripartite models, with few exceptions. Just one study of ﬁve evaluated 
fulﬁlled he criteria for good test-retest reliability. However, most of the studies report-
ing alpha revealed an acceptable level of internal consistency reliability. CONCLU-
SIONS: Based on the studies in the review, the ﬁndings suggest that the HADS may 
be an effective screening tool in an alcohol dependent population, though there is a 
caveat to this. The test-retest characteristics appear unsatisfactory in the studies 
selected. Notwithstanding the test-retest reliability characteristics, factor structure and 
internal consistency evidence would suggest the instrument to be suitable for use in 
an alcohol-dependent population.
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OBJECTIVES: Substantial numbers of patients presenting to primary care suffer 
unrecognized disorders of mood or anxiety, potentially complicating treatment and 
outcome. The objective of this study was to evaluate the validity of an electronic 
screening instrument based upon the World Health Organization’s Composite Inter-
national Diagnostic Interview (WHO CIDI) and DSM-IV-TR designed for use in 
primary care. This is a fully-structured computerized instrument designed to screen 
for bipolar disorder (BPD), generalized anxiety disorder (GAD), panic disorder (PD) 
and major depressive episodes (MDE) in primary care patients. METHODS: A pre-
liminary version of the instrument was piloted in individuals with known disease. 
Following cognitive interviews with subjects, it was reﬁned and tested in 3058 respon-
dents from 29 primary care physician ofﬁces across the US. Sub-samples were selected 
to receive a reappraisal interview (n = 206), over-sampling on those screening positive 
for either the disorders. To assess validity each completed a “gold-standard” Struc-
tured Clinical Interview for DSM (SCID) administered via phone by trained clinicians. 
RESULTS: Individual-level concordance was good between the screener diagnoses and 
the SCID assessments. Area under the receiver operating characteristic curve (AUC), 
a measure of classiﬁcation accuracy not inﬂuenced by disorder prevalence) demon-
strated substantial agreement for MDE (AUC = 0.85). BPD initially demonstrated 
fair-moderate agreement (AUC = .78), but this was improved to the “substantial” 
range (AUC = 0.86) with the enhancement of history of lifetime mania in the SCID 
interview. PD and GAD both demonstrated fair-moderate agreement (AUC = 0.79 
and AUC = 0.67; respectively). CONCLUSIONS: The results demonstrate that the 
CIDI-based computerized screening instrument can be used to identify the vast major-
ity of patients with a high likelihood of mood and anxiety disorders treated in the 
primary care setting.
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OBJECTIVES: The DAS-A is an 8-item patient-reported instrument designed to detect 
daily changes of anxiety symptoms in patients with Generalized Anxiety Disorder 
(GAD) during the ﬁrst week of treatment. This study compared the psychometric and 
measurement properties of an IVR version of the DAS-A with the original paper 
version. METHODS: Adult patients with GAD were enrolled at the screening visit of 
a clinical trial. Treatment randomization occurred at day 0. Patients were scheduled 
to complete the IVR DAS-A from day −6 through day 7. Paper-and-pencil DAS-A 
forms were completed by selected patients during clinic visits on days 0, 4 and 7. 
Psychometric properties of both DAS-A forms were compared with respect to internal 
scale consistency (Chronbach’s alpha), item reliability (intraclass correlation coefﬁ-
cient; ICC), and mean score equivalence when both formats were administered within 
24 hours of each other (paired t-tests). RESULTS: A total of 2804 IVR DAS-A assess-
ments and 119 paper DAS-A forms were completed. In 62 instances both formats 
were completed within 24 hours of one another. Cronbach’s alpha across all IVR 
DAS-A administrations was 0.85; the mean ICC was 0.84 (95% CI = 0.83–0.85). 
Cronbach’s alpha across all paper DAS-A administrations was 0.90; the mean ICC 
was 0.89 (95% CI = 0.86–0.92). The mean (± SD) IVR and paper DAS-A total scores 
were 58.97 (± 20.09) and 60.91 (± 21.00), respectively; this difference was not statisti-
cally signiﬁcant, t = 1.89, p. = 0.06. The correlation between the DAS-A total scores 
was 0.90, p. < 0.001. Comparisons between DAS-A formats at an item-by-item level 
found signiﬁcant inter-method correlations (range 0.59 to 0.79); one item identiﬁed a 
potentially signiﬁcant difference in mean score, t = 2.05, p. = 0.04, but likely reﬂects 
Type I error inﬂation. CONCLUSIONS: This analysis supports the equivalence of the 
IVR and paper DAS-A formats for measuring daily changes of anxiety symptoms in 
patients with GAD.
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OBJECTIVES: Intensive cognitive interviews are valuable in the reﬁnement of patient 
reported outcome (PRO) instruments and can identify how patients perceive the 
meaning of questions, how they develop and justify their responses and can allow the 
researcher to test face validity and burden of the instrument. We conducted intensive 
cognitive interviews with outpatients diagnosed with schizophrenia to reﬁne the clear 
thinking scale (CTS)—a recently validated PRO instrument that assesses patient prefer-
ences and functioning across four sub-domains (staying organized; making sense of 
the world; feeling clear headed; and expressing thoughts and feelings). METHODS: 
Intensive cognitive interviews were conducted by an experienced interviewer at various 
facilities associated with Johns Hopkins. Following the consenting process, partici-
pants completed the preferences (5 items) and functioning (28 items) components of 
the CTS. Concurrent and retrospective verbal probing was utilized to assess the 
respondent level of understanding and burden. All interviews were recorded, tran-
scribed and analyzed using phenomenological qualitative methods. RESULTS: A total 
of 20 patients with a primary diagnosis of diagnosis of schizophrenia or schizoaffective 
disorder participated in the study. While respondents regularly got off topic and often 
lacked conﬁdence in their answers, we found a relatively consistent interpretation of 
items across respondents. We also identiﬁed several approaches to improving the CTS 
scale, including: 1) simplifying items and avoiding compounded items; 2) repeating 
the time frame (i.e., in the past week) before every question; 3) supporting response 
variables with numbers/details; 4) using rankings rather than ratings to elicit patient 
preferences; 5) avoiding items that might have a literal interpretation; 6) measuring 
functioning prior to measuring preferences; and 7). having an example question for 
both functioning and preferences questions. CONCLUSIONS: Despite its difﬁculties, 
intensive cognitive interviewing among patients diagnosed with schizophrenia pro-
vided valuable information for the reﬁnement of the CTS and other future PRO scales.
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OBJECTIVES: To assess the impact of “equivalent substitution” (true generic of the 
prescribed drug) or “non-equivalent substitution” (switch to another agent, brand or 
generic) on perceptions, attitudes, and treatment adherence in patients with and 
without depression and anxiety disorder. METHODS: Over 10,000 randomly-selected 
US respondents from the 2007 National Health and Wellness Survey (NWHS) com-
pleted a self-administered, internet-based survey. The subpopulation of 2360 self-
identiﬁed anxious/depressed respondents was supplemented with 5539 re-contacted 
self-identiﬁed anxious/depressed responders from the 2006/2007 NWHS. Responses 
from non-anxious/depressed patients were compared to those of self-identiﬁed 
anxious/depressed patients using t-tests, ANOVA, and multiple linear and logistic 
regressions. Comparisons were also made between anxious/depressed subgroups. 
RESULTS: A total of 52% of non-anxious/depressed patients experienced therapeutic 
substitution; 50% reported equivalent and 18% to non-equivalent substitutions (dif-
ferent brand—10%, generic of another agent—8%). 51% of the non-anxious/
depressed and 71.5% of the anxious/depressed patients have experienced switching. 
More anxious/depressed patients found required step therapy unacceptable (P < 0.001; 
many tried to change health plans for this reason.77% of non-anxious/depressed and 
81% of anxious/depressed patients considered equivalent substitution (an equivalent 
generic) acceptable, but only about half in both groups thought that non-equivalent 
substitution was acceptable. Substitution affected attitudes and treatment adherence 
signiﬁcantly more in anxious/depressed vs. non-anxious/depressed patients. Impor-
tantly, anxious/depressed patients subjected to non-equivalent substitution reported 
signiﬁcantly lower treatment adherence than those who were not (P < 0.001). Switch-
ing to a non-equivalent generic also reduced adherence more than switching to an 
equivalent generic (P < 0.0001) in this population. CONCLUSIONS: About half of 
all respondents found required step therapy unacceptable. Anxious/depressed patients 
reported signiﬁcant deterioration of treatment adherence and treatment-related atti-
tudes following equivalent, and especially non-equivalent substitution. Substitution of 
prescribed drugs for depression or anxiety disorders negatively affected self-reported 
treatment adherence in the treated population, which may impact treatment 
outcomes.
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OBJECTIVES: This study examined the extent of functional impairment in children 
and adolescents aged 5 to 17 years with depression based on 2005–2006 Medical 
Expenditure Panel Survey (MEPS) data. METHODS: This study involved retrospective 
